Home - Stemline Therapeutics
At Stemline, we are committed to applying our scientific leadership to transform the lives of people with cancer. We are focused on the development of a broad pipeline of innovative, transformative therapies in oncology.
About Us - Stemline Therapeutics
The goal of our dedicated team of scientists, specialists, researchers, and developers is to build a leading biopharmaceutical company focused on improving the lives of cancer patients by developing and commercializing novel first-in-class therapeutics.
Stemline Therapeutics, a subsidiary of Menarini Group ...
Stemline Therapeutics (“Stemline”), a wholly-owned subsidiary of the Menarini Group, headquartered in New York and focused on bringing transformational oncology treatments for cancer patients, will commercialize ORSERDU in the U.S.
Menarini Group to Acquire Stemline Therapeutics in ...
Menarini Group and Stemline Therapeutics Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, (Nasdaq: STML) today announced a definitive agreement under which Menarini G.
Menarini Group Completes Acquisition of Stemline Therapeutics
Jun 10, 2020 · Acquisition of Stemline establishes Menarini’s presence in the U.S. biopharmaceutical oncology market. Menarini will support further development of Stemline’s ELZONRIS® and enable global expansion by leveraging its commercial infrastructure in Europe and other ex-U.S. geographies.
Product Pipeline - Stemline Therapeutics
Stemline is investing in advanced science and technology to develop a pipeline of new products that make a difference to the lives of patients affected by cancer. Our pipeline refers to drugs in development, including those in preclinical testing, clinical development, regulatory approval and lifecycle management.
Menarini Stemline - LinkedIn
Inspired by the goal to improve outcomes for those with unmet medical needs, Menarini Stemline is driven to discover and develop innovative therapeutics for the treatment of cancer.
Menarini Group Completes Acquisition of Stemline Therapeutics
Jun 10, 2020 · Stemline launched ELZONRIS for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult and pediatric patients, two years or older, following the approval by the United ...
FDA approves elacestrant for ER-positive, HER2-negative, ESR1 ...
On January 27, 2023, the Food and Drug Administration (FDA) approved elacestrant (Orserdu, Stemline Therapeutics, Inc.) for postmenopausal women or adult men with ER-positive, HER2-negative,...
Menarini Group’s Stemline inks $500M+ biobucks deal for ...
Jan 4, 2024 · Menarini Group’s Stemline Therapeutics is paying $12 million upfront for licensing rights to Insilico Medicine’s breast cancer candidate in a deal potentially worth more than $500 million.